Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07415031

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Solid Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Local Institution - 0093, St Leonards, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
  • Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.

Exclusion criteria

  • Participant is not eligible for study treatment per the parent study eligibility criteria.
  • Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study.
  • Participants not receiving clinical benefit from parent study drug as assessed by the investigator.

Other protocol defined inclusion/exclusion criteria applies.

Treatment and study plan

Adagrasib

Drug

Specified dose on specified days

Other names: BMS-986503

Pembrolizumab

Drug

Specified dose on specified days

Cetuximab

Drug

Specified dose on specified days

Pemetrexed

Drug

Specified dose on specified days

docetaxel

Drug

Specified dose on specified days

Irinotecan

Drug

Specified dose on specified days

Leucovorin

Drug

Specified dose on specified days

Other names: Folinic acid

Oxaliplatin

Drug

Specified dose on specified days

Fluorouracil

Drug

Specified dose on specified days

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Up to 90 days from last dose or study discontinuation

  2. Number of Participants With AEs Leading to Treatment Discontinuation

    Time frame: Up to 90 days from last dose or study discontinuation

  3. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to 90 days from last dose or study discontinuation

  4. Number of Participants With AEs Leading to Death

    Time frame: Up to 90 days from last dose or study discontinuation

Study contacts

Contact information is provided by the study sponsor or research team.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

CONTACT

[email protected]

855-907-3286

First line of the email MUST contain NCT # and Site #.

CONTACT

Sponsors and collaborators

Lead sponsor

Mirati Therapeutics Inc.

Industry

Registry information

Official study title

Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Feb 17, 2026
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.